A murine model of bone marrow micrometastasis in breast cancer

Barbara O'Kane Murphy, Shantaram S Joshi, Margaret Anne Kessinger, Elizabeth Cecile Reed, John G Sharp

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Bone marrow (BM) is one of the most common sites and often the first clinical indication of metastatic progression of breast cancer. Multivariate analyses have shown that the presence of cytokeratin positive tumor cells in the marrow of women with newly diagnosed stage I, II or III breast cancer is an independent predictor of survival. The objective of this study was to develop an orthotopic model of spontaneous BM metastasis to facilitate studies of this process. A murine mammary adenocarcinoma cell line, Clone 66, was transduced with the neomycin resistance gene (C166neo) and injected orthotopically into female Balb/c mice. Polymerase chain reaction (PCR) for the neo gene performed on BM cells harvested from tumor bearing mice demonstrated as few as 102 injected tumor cells produced BM micrometastases at 4 weeks post-injection. Small foci of tumor cells were identified in the mammary fatpad (mfp) without gross evidence of primary tumors. Higher doses of tumor cells produced BM micrometastases, detectable by PCR, at one week post-injection. Constructs containing green fluorescent protein (GFP) and the neomycin resistance gene (neo) were also transduced into Clone 66 cells (C166-GFPneo) and injected into the mfp. GFP transduced tumor cells were identified in multiple tissues in addition to BM by flow cytometric analysis (FACS) but less 13% of the animals developed gross metastases. This model is a clinically relevant tool for the analysis of organ specificity of metastasis.

Original languageEnglish (US)
Pages (from-to)561-569
Number of pages9
JournalClinical and Experimental Metastasis
Volume19
Issue number7
DOIs
StatePublished - Dec 1 2002

Fingerprint

Neoplasm Micrometastasis
Bone Marrow
Breast Neoplasms
Neoplasms
Bone Marrow Cells
Breast
Neomycin
Neoplasm Metastasis
Green Fluorescent Proteins
Clone Cells
Genes
Polymerase Chain Reaction
Organ Specificity
Injections
Keratins
Adenocarcinoma
Multivariate Analysis
Cell Line
Survival

Keywords

  • Bone marrow metastasis
  • Breast cancer
  • Mammary tumor
  • Murine model

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A murine model of bone marrow micrometastasis in breast cancer. / O'Kane Murphy, Barbara; Joshi, Shantaram S; Kessinger, Margaret Anne; Reed, Elizabeth Cecile; Sharp, John G.

In: Clinical and Experimental Metastasis, Vol. 19, No. 7, 01.12.2002, p. 561-569.

Research output: Contribution to journalArticle

@article{d12207419a8b4deeb50b046290a032f8,
title = "A murine model of bone marrow micrometastasis in breast cancer",
abstract = "Bone marrow (BM) is one of the most common sites and often the first clinical indication of metastatic progression of breast cancer. Multivariate analyses have shown that the presence of cytokeratin positive tumor cells in the marrow of women with newly diagnosed stage I, II or III breast cancer is an independent predictor of survival. The objective of this study was to develop an orthotopic model of spontaneous BM metastasis to facilitate studies of this process. A murine mammary adenocarcinoma cell line, Clone 66, was transduced with the neomycin resistance gene (C166neo) and injected orthotopically into female Balb/c mice. Polymerase chain reaction (PCR) for the neo gene performed on BM cells harvested from tumor bearing mice demonstrated as few as 102 injected tumor cells produced BM micrometastases at 4 weeks post-injection. Small foci of tumor cells were identified in the mammary fatpad (mfp) without gross evidence of primary tumors. Higher doses of tumor cells produced BM micrometastases, detectable by PCR, at one week post-injection. Constructs containing green fluorescent protein (GFP) and the neomycin resistance gene (neo) were also transduced into Clone 66 cells (C166-GFPneo) and injected into the mfp. GFP transduced tumor cells were identified in multiple tissues in addition to BM by flow cytometric analysis (FACS) but less 13{\%} of the animals developed gross metastases. This model is a clinically relevant tool for the analysis of organ specificity of metastasis.",
keywords = "Bone marrow metastasis, Breast cancer, Mammary tumor, Murine model",
author = "{O'Kane Murphy}, Barbara and Joshi, {Shantaram S} and Kessinger, {Margaret Anne} and Reed, {Elizabeth Cecile} and Sharp, {John G}",
year = "2002",
month = "12",
day = "1",
doi = "10.1023/A:1020958915361",
language = "English (US)",
volume = "19",
pages = "561--569",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "7",

}

TY - JOUR

T1 - A murine model of bone marrow micrometastasis in breast cancer

AU - O'Kane Murphy, Barbara

AU - Joshi, Shantaram S

AU - Kessinger, Margaret Anne

AU - Reed, Elizabeth Cecile

AU - Sharp, John G

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Bone marrow (BM) is one of the most common sites and often the first clinical indication of metastatic progression of breast cancer. Multivariate analyses have shown that the presence of cytokeratin positive tumor cells in the marrow of women with newly diagnosed stage I, II or III breast cancer is an independent predictor of survival. The objective of this study was to develop an orthotopic model of spontaneous BM metastasis to facilitate studies of this process. A murine mammary adenocarcinoma cell line, Clone 66, was transduced with the neomycin resistance gene (C166neo) and injected orthotopically into female Balb/c mice. Polymerase chain reaction (PCR) for the neo gene performed on BM cells harvested from tumor bearing mice demonstrated as few as 102 injected tumor cells produced BM micrometastases at 4 weeks post-injection. Small foci of tumor cells were identified in the mammary fatpad (mfp) without gross evidence of primary tumors. Higher doses of tumor cells produced BM micrometastases, detectable by PCR, at one week post-injection. Constructs containing green fluorescent protein (GFP) and the neomycin resistance gene (neo) were also transduced into Clone 66 cells (C166-GFPneo) and injected into the mfp. GFP transduced tumor cells were identified in multiple tissues in addition to BM by flow cytometric analysis (FACS) but less 13% of the animals developed gross metastases. This model is a clinically relevant tool for the analysis of organ specificity of metastasis.

AB - Bone marrow (BM) is one of the most common sites and often the first clinical indication of metastatic progression of breast cancer. Multivariate analyses have shown that the presence of cytokeratin positive tumor cells in the marrow of women with newly diagnosed stage I, II or III breast cancer is an independent predictor of survival. The objective of this study was to develop an orthotopic model of spontaneous BM metastasis to facilitate studies of this process. A murine mammary adenocarcinoma cell line, Clone 66, was transduced with the neomycin resistance gene (C166neo) and injected orthotopically into female Balb/c mice. Polymerase chain reaction (PCR) for the neo gene performed on BM cells harvested from tumor bearing mice demonstrated as few as 102 injected tumor cells produced BM micrometastases at 4 weeks post-injection. Small foci of tumor cells were identified in the mammary fatpad (mfp) without gross evidence of primary tumors. Higher doses of tumor cells produced BM micrometastases, detectable by PCR, at one week post-injection. Constructs containing green fluorescent protein (GFP) and the neomycin resistance gene (neo) were also transduced into Clone 66 cells (C166-GFPneo) and injected into the mfp. GFP transduced tumor cells were identified in multiple tissues in addition to BM by flow cytometric analysis (FACS) but less 13% of the animals developed gross metastases. This model is a clinically relevant tool for the analysis of organ specificity of metastasis.

KW - Bone marrow metastasis

KW - Breast cancer

KW - Mammary tumor

KW - Murine model

UR - http://www.scopus.com/inward/record.url?scp=0036906643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036906643&partnerID=8YFLogxK

U2 - 10.1023/A:1020958915361

DO - 10.1023/A:1020958915361

M3 - Article

VL - 19

SP - 561

EP - 569

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 7

ER -